½ÃÀ庸°í¼­
»óǰÄÚµå
1368677

»ý¸®½Ä¿°¼ö ½ÃÀå ±Ô¸ð : ¾àÁ¦ À¯Çü, Æ÷Àå À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, ¼¼°è ¿¹Ãø(2023-2032³â)

Physiological Saline Market Size - Drug Type (Normal Saline, Hypotonic), Packaging Type (Flexible Bag, Plastic Bottle), Application (Chronic Disease, Acute Health Conditions), End-user, Global Forecast 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ »ý¸®½Ä¿°¼ö ½ÃÀåÀº 2023-2032³â 6.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

»ý¸®½Ä¿°¼ö´Â Á¤¸ÆÁÖ»ç, »óó ¼¼Ã´ ¹× Áø´Ü ÀýÂ÷¿¡ ÇʼöÀûÀ̸ç, ÇコÄɾîÀÇ Áß¿äÇÑ ÄÄÆ÷³ÍÆ®·Î ³²¾Æ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¸¼ºÁúȯ°ú ¼ö¼ú Áõ°¡µµ ½Ä¿°¼ö ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î WHOÀÇ 2023³â 9¿ù Åë°è¿¡ µû¸£¸é ºñ°¨¿°¼º Áúȯ(NCDs)Àº ¸Å³â 4,100¸¸ ¸íÀÇ ¸ñ¼ûÀ» ¾Ñ¾Æ°¡¸ç ¼¼°è ÃÑ »ç¸Á·üÀÇ 74%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¶ÇÇÑ ¸Å³â 1,700¸¸ ¸íÀÌ 70¼¼ ÀÌÀü¿¡ NCDs·Î ÀÎÇØ »ç¸ÁÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áúº´ÀÌ Á¶±â »ç¸Á·ü¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ È£Èí±â Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ´õ¿í ³ô¾ÆÁ³½À´Ï´Ù. ȯÀÚµéÀÇ °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÚ¿¬½º·´°í ¾ÈÀüÇÑ Á¦Ç°À» ¼±È£ÇÏ´Â °æÇâÀÌ ³ô¾ÆÁ® ½Ä¿°¼ö¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ½Ä¿°¼ö ½ÃÀå Àü¸ÁÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ ºÐ¾ß´Â 2023-2032³â Å©°Ô ¹ßÀüÇÒ °ÍÀÔ´Ï´Ù. ÀÌ ¹«±ÕÀÇ ±ÕÇü ÀâÈù ¼Ò±Ý ¿ë¾×Àº ´ç´¢º´, ½ÅÀå Áúȯ, ½ÉÇ÷°ü Áúȯ°ú °°Àº ´Ù¾çÇÑ ¸¸¼º °Ç°­ »óÅÂÀÇ Ä¡·á ¹× °ü¸®¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¼¼°è¿¡¼­ ¸¸¼ºÁúȯÀÇ ºÎ´ãÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó »ý¸®½Ä¿°¼ö ½ÃÀå¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó °ß°íÇÏ°Ô À¯ÁöµÇ°í ÀÖÀ¸¸ç, ÇコÄɾ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ºÎ¹®Àº 2023-2032³â µÎµå·¯Áø CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿Ü·¡ ¼ö¼ú¿¡ ÁßÁ¡À» µÐ ÀÌµé ½Ã¼³Àº ¼ö¼ú Àü ¼öºÐ °ø±Þ, »óó °ü°³, ¼ö¼ú ÈÄ °ü¸® µî ´Ù¾çÇÑ ÀÇ·á¿ë ½Ä¿°¼ö¸¦ »ç¿ëÇϰí ÀÖÀ¸¸ç, ASCÀÇ ¼ºÀå Ãß¼¼¿¡ µû¶ó ½Ä¿°¼ö ½ÃÀå Á¡À¯À²Àº °ß°íÇÏ°Ô À¯ÁöµÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ È¯°æ¿¡¼­ ¾ÈÀüÇϰí È¿°úÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ »ý¸®½Ä¿°¼ö ½ÃÀåÀº 2023-2032³â µÎµå·¯Áø CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ´ë·úÀÇ °í·ÉÈ­´Â ¸¸¼ºÁúȯ Áõ°¡¿Í ÇÔ²² ÀÇ·á ȯ°æ¿¡¼­ ½Ä¿°¼ö ¼Ö·ç¼ÇÀÇ Çʿ伺À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î À¯·Î½ºÅ¸Æ®(Eurostat)ÀÇ º¸°í¼­¿¡ µû¸£¸é ¿¬·Éº° ¿¹Ãø¿¡ µû¸£¸é 2050³â±îÁö EU-27¿¡¼­ °ÅÀÇ 50¸¸ ¸íÀÇ ¹é¼ö Àα¸°¡ ź»ýÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´ÀÇ ³ôÀº ÀÇ·á ¼öÁØÀº ¾ö°ÝÇÑ ¾ÈÀü ±ÔÁ¦¿Í ÇÔ²² ½Ä¿°¼öÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ÇàÀ§°¡ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ÀÌ Çʼö ÀÇ·á Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä´Â À¯·´ ÀÇ·á ȯ°æ¿¡¼­ °è¼Ó °ß°íÇÏ°Ô À¯ÁöµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

  • ½ÃÀåÀÇ Á¤ÀÇ
  • ±âº» ÃßÁ¤°ú °è»ê
  • ¿¹Ãø ÆÄ¶ó¹ÌÅÍ
  • ¼¼°è ·¹º§¿¡¼­ÀÇ COVID-19 ¿µÇ⠺м®
  • µ¥ÀÌÅÍ °ËÁõ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ µ¥ÀÌÅÍ
    • 2Â÷ µ¥ÀÌÅÍ
      • À¯·á Á¤º¸¿ø
      • °øÀû Á¤º¸¿ø

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ý¸®½Ä¿°¼ö »ê¾÷ ÀλçÀÌÆ®

  • ¾÷°è »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯÀÇ Áõ°¡
      • ÀÇ·á ¹× ¿Ü°ú¼ö¼úÀÇ Áõ°¡
      • ÀǷᡤÇコÄÉ¾î ¿ëµµÀÇ Áõ°¡
      • Á¦Ç° ¾ÈÀü¼º°ú °¡¿ë¼º¿¡ ÀÇÇÑ ³ôÀº äÅ÷ü
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • »ý¸®½Ä¿°¼öÀÇ ºñ¿ë Á¦¾à
      • ´ëü ¼Ö·ç¼ÇÀÇ Áõ°¡
      • ¹«±Õ¼º°ú ¿À¿° ¹®Á¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå »ý¸®½Ä¿°¼ö ½ÃÀå : À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • ÀÏ¹Ý ½Ä¿°¼ö
  • °íÀå½Ä¿°¼ö
  • ÀúÀå½Ä¿°¼ö

Á¦6Àå »ý¸®½Ä¿°¼ö ½ÃÀå : Æ÷Àå À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Æ÷Àå À¯Çüº°
  • ÇÃ¶ó½ºÆ½º´
  • Ç÷º¼­ºí ¹é
  • À¯¸®º´

Á¦7Àå »ý¸®½Ä¿°¼ö ½ÃÀå : ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • ±Þ¼º Áúȯ
  • ¸¸¼ºÁúȯ
  • ÇǺΠÂû°ú»ó ¹× È­»ó
  • ±âŸ ¿ëµµ

Á¦8Àå »ý¸®½Ä¿°¼ö ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå »ý¸®½Ä¿°¼ö ½ÃÀå : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • B Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Hospira(Pfizer)
  • Grifols, S.A.
  • ICU Medical, Inc.
  • Cardinal Health, Inc.
  • China Resources Double-crane Pharmaceutical Co., Ltd.
  • Amanta Healthcare
KSA 23.11.14

Global Physiological Saline Market will witness 6.2% CAGR between 2023 and 2032. it remains a crucial component in healthcare, essential for intravenous fluids, wound cleansing, and diagnostic procedures. In addition, the rising prevalence of chronic diseases and surgical interventions contributes to increased demand for saline solutions.

For instance, according to September 2023 stats from WHO, noncommunicable diseases (NCDs) claim the lives of 41 million individuals annually, accounting for 74% of the total global mortality. Furthermore, each year, 17 million people succumb to NCDs before reaching the age of 70, underscoring the significant impact of these diseases on premature mortality. Furthermore, the COVID-19 pandemic highlighted its use for respiratory care. As patients become more health-conscious, there's a growing preference for natural and safe products, boosting the demand for physiological saline solutions. These factors collectively propel the physiological saline market outlook.

The overall Physiological Saline Market is classified based on application, end-user, and region.

The chronic diseases segment will undergo significant development from 2023 to 2032. This sterile and balanced salt solution plays a pivotal role in the treatment and management of various chronic health conditions, such as diabetes, kidney disease, and cardiovascular issues. As the global burden of chronic diseases continues to rise, the physiological saline market demand remains robust, making it an indispensable component in healthcare.

The ambulatory surgical centers segment will register a commendable CAGR from 2023 to 2032. These facilities, focused on outpatient procedures, rely on saline solutions for various medical applications, including pre-operative hydration, wound irrigation, and post-operative care. As the trend toward ASCs continues to grow, the physiological saline market share remains strong, supporting its crucial role in providing safe and effective healthcare in these settings.

Europe physiological saline market will showcase an appreciable CAGR from 2023 to 2032. The continent's aging population, in line with a rising prevalence of chronic diseases, fuels the need for saline solutions in healthcare settings. For instance, according to a report from Eurostat, an age-based projection indicates that the EU-27 is expected to have nearly 500,000 centenarians by the year 2050. The high healthcare standards in Europe, in tandem with stringent safety regulations, emphasize the significance of physiological saline. As medical practices continue to evolve, the demand for this essential medical product remains robust in the European healthcare landscape.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 COVID-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data Sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Physiological saline industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Type trends
    • 2.1.4 Packaging type trends
    • 2.1.5 Application trends
    • 2.1.6 End-user trends

Chapter 3 Physiological Saline Industry Insights

  • 3.1 Industry landscape
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic diseases
      • 3.2.1.2 Increasing number of medical and surgical procedures
      • 3.2.1.3 High medical and healthcare applications
      • 3.2.1.4 High adoption due to product safety and availability
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Cost constraint for physiological saline
      • 3.2.2.2 Increasing availability of alternative solutions
      • 3.2.2.3 Sterility and contamination issues
  • 3.3 Growth potential analysis
    • 3.3.1 By type
    • 3.3.2 By packaging type
    • 3.3.3 By application
    • 3.3.4 By end-user
  • 3.4 COVID- 19 impact analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategy dashboard, 2022

Chapter 5 Physiological Saline Market, By Type, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by type
  • 5.2 Normal saline
  • 5.3 Hypertonic saline
  • 5.4 Hypotonic saline

Chapter 6 Physiological Saline Market, By Packaging Type, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by packaging type
  • 6.2 Plastic bottle
  • 6.3 Flexible bag
  • 6.4 Glass bottle

Chapter 7 Physiological Saline Market, By Application, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by application
  • 7.2 Acute health conditions
  • 7.3 Chronic diseases
  • 7.4 Skin abrasions and burns
  • 7.5 Other applications

Chapter 8 Physiological Saline Market, By End-user, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by end-user
  • 8.2 Hospitals
  • 8.3 Ambulatory surgical centers
  • 8.4 Other end-users

Chapter 9 Physiological Saline Market, By Region, 2018 - 2032 (USD Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 B Braun Melsungen AG
  • 10.2 Baxter International Inc.
  • 10.3 Fresenius Kabi AG
  • 10.4 Otsuka Pharmaceutical Co., Ltd.
  • 10.5 Hospira (Pfizer)
  • 10.6 Grifols, S.A.
  • 10.7 ICU Medical, Inc.
  • 10.8 Cardinal Health, Inc.
  • 10.9 China Resources Double-crane Pharmaceutical Co., Ltd.
  • 10.10 Amanta Healthcare
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦